Skip to main content
Clinical Trials/NCT05055505
NCT05055505CompletedNot Applicable

The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program Implemented With a Stepped-wedge Cluster Randomized Design in Elementary Schools in Low SARS-CoV-2 Incidence Regions

The Hospital for Sick Children1 site in 1 country120 target enrollmentStarted: September 14, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
120
Locations
1
Primary Endpoint
SARS-CoV-2 Case identification

Study Overview

Brief Summary

This study will conduct an evaluation of a program that is being implemented SickKids / Toronto Public health that provides take-home saliva testing kits in schools. Operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. This study will leverage this chance implementation to do a robust evaluation of the public health intervention. Schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center, primary care or acute care facility) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. The investigators will evaluate the impact of the program on SARS-CoV-2 case identification in schools.

Detailed Description

This is a prospective evaluation of a program that is being implemented using a stepped-wedge, cluster randomized design.

Eligible elementary public schools Toronto Region in low SARS-CoV-2 incidence regions (quintiles 1,2 or 3) will be randomized. The study will occur over a 7-week period with a minimum of one-week of baseline data (control phase - testing at an assessment center, primary care or acute care center) and then schools will start the program in a stepwise manner (20 crossovers per week) with take-home saliva being available to all 120 schools by the end of the study period. The primary objective of the study is to assess whether the availability of take home saliva kits at schools for symptomatic testing leads to increased diagnosis of SARS-CoV-2 cases in the school.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
2 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Elementary schools will be included in the evaluation if they are:
  • •Considered an elementary school by the school board
  • •Open for in-person learning during the study period
  • •They have at least 200 students
  • •Offer at least 4 grades

Exclusion Criteria

  • •Schools that are middle schools only, that are not open for in-person learning, have fewer than 200 students or are not a complete elementary school (i.e.schools offering independent courses, prep schools with 1-2 grades, elementary schools with < 4 grades) will be excluded.

Arms & Interventions

control phase

No Intervention

Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.

Intervention phase

Active Comparator

Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.

Intervention: Take home saliva kits (Diagnostic Test)

Outcomes

Primary Outcomes

SARS-CoV-2 Case identification

Time Frame: Weekly measurement over 7 week study period

The number of cases positive for SARS-CoV-2 in a cohort per week per school

Secondary Outcomes

  • Uptake of take-home saliva kits for testing(Weekly measurement over 7 week study period)
  • Impact on timing of test for symptomatic individuals(Over 7 week study period)
  • Impact on secondary transmission(Over 7 week study period)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Michelle Science

Principle Investigator

The Hospital for Sick Children

Study Sites (1)

Loading locations...

Similar Trials